Microglia are central players in brain innate immunity and have been the subject of extensive research in Alzheimer’s disease (AD). In this review, we aim to summarize the genetic and functional discoveries that have advanced our understanding of microglia reactivity to AD pathology. Given the heightened AD risk posed by rare variants of the microglial triggering receptor expressed on myeloid cells 2 (TREM2), we will focus on the studies addressing the impact of this receptor on microglia responses to amyloid plaques, tauopathy and demyelination pathologies in mouse and human. Finally, we will discuss the implications of recent discoveries on microglia and TREM2 biology on potential therapeutic strategies for AD.

Original languageEnglish
Article number84
JournalMolecular neurodegeneration
Issue number1
StatePublished - Dec 2022


  • APOE
  • Alzheimer’s disease
  • Beta-amyloid pathology
  • Demyelination
  • Microglia
  • TREM2
  • Tauopathy


Dive into the research topics of 'TREM2 dependent and independent functions of microglia in Alzheimer’s disease'. Together they form a unique fingerprint.

Cite this